Harmony Biosciences (HRMY) Tops Q4 EPS by 28c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.63, $0.28 better than the analyst estimate of $0.35. Revenue for the quarter came in at $91.2 million versus the consensus estimate of $91.33 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance